Companion Diagnostics Market Companion Diagnostics Market Dublin, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The "Companion ...

Kepler Capital analyst Maja Pataki maintained a Hold rating on Qiagen (QGEN – Research Report) on February 6 and set a price target of €42.17.

QIAGEN N.V.’s QGEN long-term business strategy focuses on forming partnerships for the development, commercialization, marketing and distribution of existing and future products. The company ...

The FDA also approved the therascreen KRAS RGQ PCR Kit (QIAGEN GmbH) as a companion diagnostic device for identifying eligible patients. Approval of sotorasib with panitumumab was based on ...

The FDA also approved the therascreen KRAS RGQ PCR Kit (QIAGEN GmbH) as a companion diagnostic device to aid in identifying patients with colorectal cancer whose tumors harbor KRAS G12C mutations and ...

In a related action, the FDA approved the therascreen KRAS RGQ PCR Kit (QIAGEN GmbH) as a companion diagnostic device to help determine which patients with colorectal cancer have tumors that ...

DNA from frozen mESCs pellets was extracted using DNeasy Blood and Tissue Kit (Qiagen GmbH, Hilden, Germany). Purified genomic DNA was quantified with Qubit (Invitrogen, Carlsbad, CA, USA) according ...

QIAGEN announced earlier in January plans for the repurchase, which comes after QIAGEN returned approximately $300 million to shareholders in early 2024 also through a synthetic share repurchase.

The agency also gave the green light to therascreen KRAS RGQ PCR Kit (QIAGEN GmbH) for use as a companion diagnostic device to assist in the identification of patients with CRC whose tumors harbor ...